Details of the Drug

General Information of Drug (ID: DMTWUXR)

• Drug Name: Chlormezanone
• Synonyms: Alinam; Banabin; Bisina; Chlomedinon; Chlormethazanone; Chlormethazone; Chlormezanon; Chlormezanona; Chlormezanonum; Clorilax; Clormetazanone; Clormetazon; Clormezanona; Clormezanone; Dichloromethazanone; Dichloromezanone; Lobak; Miorilax; Muskel; Myolespen; Phenarol; Rexan; Rilansyl; Rilaquil; Rilasol; Rilassol; Rilax; Rillasol; Supotran; Suprotan; Tanafol; Trancopal; Trancote; Tranrilax; Transanate; Clormezanone [DCIT]; WIN 4692; Banabil-sintyal; Banabin-sintyal; Banabin-syntyal; C-192; Chlormezanonum [INN-Latin]; Clormezanona [INN-Spanish]; Dl-Chlormezanone; Mio-sed; Muskel-Trancopal; TRANCOPAL (TN); Trancopal (TN); Chlormezanone (JAN/INN); Chlormezanone [BAN:INN:JAN]; Chlormezanone [INN:BAN:JAN]; (+-)-Chlormezanone; 2-(4-Chlorophenyl)-3-methyl-1,3-thiazinan-4-one 1,1-dioxide; 2-(4-Chlorophenyl)-3-methyl-4-metathiazanone-1,1-dioxide; 2-(4-Chlorophenyl)tetrahydro-3-methyl-4H,1,3-thiazin-4-one 1,1-Dioxide; 2-(4-Chlorophenyl)tetrahydro-3-methyl-4H-1,3-thiazin-4-one 1,1-dioxide; 2-(4-Chlorphenyl)-3-methyl-4-metathiazanon-1,1-dioxid; 2-(4-chlorophenyl)-3-methyl-1,1-dioxo-1,3-thiazinan-4-one; 2-(p-Chlorophenyl)tetrahydro-3-methyl-4H-1,3-thiazin-4-one 1,1-dioxide; 2-(p-Chlorphenyl)-3-methyl-1,3-perhydrothiazin-4-on-1,1-dioxide; 2-(para-Chlorophenyl)tetrahydro-3-methyl-4H-1,3-thiazin-4-one, 1,1-dioxide; 4H-1,3-Thiazin-4-one, 2-(4-chlorophenyl)tetrahydro-3-methyl-, 1,1-dioxide; 4H-1,3-Thiazin-4-one, 2-(4-chlorophenyl)tetrahydro-3-methyl-1,1-dioxide; 4H-1,3-Thiazin-4-one, 2-(p-chlorophenyl)tetrahydro-3-methyl-, 1,1,-dioxide; 4H-1,3-Thiazin-4-one, 2-(p-chlorophenyl)tetrahydro-3-methyl-, 1,1-dioxide; 4H-1,3-Thiazin-4-one, 2-(p-chlorophenyl)tetrahydro-3-methyl-1,1-dioxide; 4H-1,3-Thiazin-4-one, tetrahydro-2-(p-chlorophenyl)-3-methyl-, 1,1-dioxide

Indication

Disease Entry	ICD 11	Status	REF
Anxiety disorder	6B00-6B0Z	Approved	[1]

• Therapeutic Class: Analgesics
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 273.74
  Logarithm of the Partition Coefficient (xlogp); 1.1
  Rotatable Bond Count (rotbonds); 1
  Hydrogen Bond Donor Count (hbonddonor); 0
  Hydrogen Bond Acceptor Count (hbondacc); 3
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
  Bioavailability: 99% of drug becomes completely available to its intended biological destination(s) [3]
• Chemical Identifiers:
  Formula: C11H12ClNO3S
  IUPAC Name: 2-(4-chlorophenyl)-3-methyl-1,1-dioxo-1,3-thiazinan-4-one
  Canonical SMILES: CN1C(S(=O)(=O)CCC1=O)C2=CC=C(C=C2)Cl
  InChI: InChI=1S/C11H12ClNO3S/c1-13-10(14)6-7-17(15,16)11(13)8-2-4-9(12)5-3-8/h2-5,11H,6-7H2,1H3
  InChIKey: WEQAYVWKMWHEJO-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 2717
  ChEBI ID: CHEBI:3619
  CAS Number: 80-77-3
  DrugBank ID: DB01178
  TTD ID: D0S1OE
  INTEDE ID: DR2270

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Translocator protein (TSPO)	TTPTXIN	TSPO_HUMAN	Agonist	[4]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Chlormezanone (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Oliceridine	DM6MDCF	Major	Additive CNS depression effects by the combination of Chlormezanone and Oliceridine.	Acute pain [MG31]	[5]
Dihydrocodeine	DMB0FWL	Major	Additive CNS depression effects by the combination of Chlormezanone and Dihydrocodeine.	Chronic pain [MG30]	[5]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Chlormezanone and Esketamine.	Depression [6A70-6A7Z]	[6]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Chlormezanone and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[7]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Chlormezanone and Lasmiditan.	Migraine [8A80]	[8]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Chlormezanone and Flibanserin.	Mood disorder [6A60-6E23]	[9]
Oxymorphone	DM65AGJ	Major	Additive CNS depression effects by the combination of Chlormezanone and Oxymorphone.	Pain [MG30-MG3Z]	[10]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7323).
• [2] BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
• [3] Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
• [4] Successful treatment of anxiety with a single night-time dose of chlormezanone: double-blind comparison with diazepam. Curr Med Res Opin. 1982;8(1):33-8.
• [5] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
• [6] Cerner Multum, Inc. "Australian Product Information.".
• [7] Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
• [8] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
• [9] Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
• [10] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".